arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Omeros Corporation

OMER Health Care Biotechnology: Pharmaceutical Preparations
$16.57
▲ +1.9% Today
as of Oct 23, 16:51 ET
Last 30 days -5.10% Sep 14 → Oct 23
$15.81 $17.22 $18.62 $20.03 $21.44 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$16.80
High
$16.80
Low
$16.37
Volume
$698,891
Avg Vol
$2M
Mkt Cap
$1.3B
P/E (TTM)
54.00
Beta
—
52w High
$21.24
52w Low
$6.24
Div Yield
—
Shares Out
$72M

Recent Press Releases & News last 60 days · 11 items

Oct 16 · 19:24 Stocktwits
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
Oct 16 · 18:25 MT Newswires
Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency
Oct 16 · 12:40 InvestorsHub
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
▸ Show all 11 press releases & news Free account →

OMER earnings at a glance

The options market is pricing a move of about ±8.5% after the report, a range of roughly $15.16 to $17.98 from today's $16.57. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±1.5% on average; after the most recent report on May 13, 2026 it moved -2.6%. That means options currently expect more movement than OMER has typically delivered. OMER beat the consensus EPS estimate in 3 of its last 3 reported quarters. Implied volatility is currently 72%. The share price of $16.57 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$6.24
$21
69% of range
Avg surprise (last 3)
+37.0%
Avg reaction (last 2)
-1.0%
50% positive
Latest IV / EM
72%
EM ±8.5% · $19 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.97$-0.69$-0.41$-0.13$0.15 Actual $-0.54Actual $-0.59Actual $-0.63Actual $-0.97Actual $-0.56Actual $-0.65Actual $-0.53Est $-0.55Actual $-0.19Est $-0.58Actual $-0.24Est $-0.40Actual $0.15 MarJunMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-33M$-10M$13M$36M$59M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $0.15 — — — — financials
Wed May 13, 2026Mar/2026 $-0.24 $-0.40 +40.0% +63.1% -2.6% earnings
Thu Nov 13, 2025Sep/2025 $-0.19 $-0.58 +67.2% — — earnings
Thu Aug 14, 2025Jun/2025 $-0.53 $-0.55 +3.6% — — earnings
Thu May 15, 2025Mar/2025 $-0.65 — — — +0.5% earnings
Mon Sep 30, 2024Sep 2024 $-0.56 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.97 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.63 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.59 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.54 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$29M$10M——$0$0——
Cost of revenue$798,000$587,000——$0$0——
Gross profit————————
Operating income$74,000$-17M—$-26M$-32M$-35M—$-35M
Net income$13M$56M—$-31M$-25M$-33M—$-32M
EPS (diluted)$0.15$0.62—$-0.47$-0.43$-0.58—$-0.56

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$2M$2M$10M$2M$2M$4M$3M$2M
Inventory$842,000$183,000$0—————
Total current assets$185M$180M$216M$72M$70M$96M$134M$165M
Total assets$287M$286M$326M$186M$201M$235M$277M$313M
Long-term debt———$155M$155M$165M—$165M
Total liabilities————————
Total equity$-51M$-63M$-121M$-220M$-229M$-214M$-183M$-154M

Implied volatility — last 90 days

44%124%204%283%363% Jun 07 — IV 140% · EM ±19.4%Jun 08 — IV 108% · EM ±14.3%Jun 09 — IV 130% · EM ±16.3%Jun 10 — IV 113% · EM ±13.3%Jun 11 — IV 112% · EM ±12.3%Jun 12 — IV 175% · EM ±17.9%Jun 15 — IV 130% · EM ±9.4%Jun 16 — IV 222% · EM ±13.1%Jun 17 — IV 99% · EM ±4.1%Jun 19 — IV 123% · EM ±27.2%Jun 22 — IV 114% · EM ±23.7%Jun 23 — IV 94% · EM ±19.2%Jun 24 — IV 114% · EM ±22.9%Jun 25 — IV 139% · EM ±27.2%Jun 26 — IV 99% · EM ±18.9%Jun 29 — IV 124% · EM ±21.9%Jun 30 — IV 98% · EM ±16.8%Jul 01 — IV 97% · EM ±16.2%Jul 02 — IV 72% · EM ±11.6%Jul 03 — IV 74% · EM ±11.6%Jul 06 — IV 100% · EM ±13.8%Jul 07 — IV 114% · EM ±15.0%Jul 08 — IV 74% · EM ±9.3%Jul 09 — IV 95% · EM ±11.2%Jul 10 — IV 68% · EM ±7.5%Jul 13 — IV 101% · EM ±8.4%Jul 14 — IV 46% · EM ±3.3%Jul 15 — IV 56% · EM ±3.3%Jul 16 — IV 364% · EM ±15.2%Jul 20 — IV 114% · EM ±27.0%Jul 21 — IV 98% · EM ±22.8%Jul 22 — IV 122% · EM ±27.9%Jul 23 — IV 115% · EM ±25.9%Jul 24 — IV 97% · EM ±21.4%Jul 27 — IV 119% · EM ±24.8%Jul 28 — IV 97% · EM ±19.8%Jul 29 — IV 97% · EM ±19.5%Jul 30 — IV 129% · EM ±25.3%Jul 31 — IV 109% · EM ±20.9%Aug 03 — IV 119% · EM ±21.1%Aug 04 — IV 116% · EM ±19.9%Aug 05 — IV 119% · EM ±20.0%Aug 06 — IV 99% · EM ±16.0%Aug 07 — IV 95% · EM ±14.9%Aug 10 — IV 138% · EM ±19.1%Aug 11 — IV 145% · EM ±19.1%Aug 12 — IV 155% · EM ±19.4%Aug 13 — IV 78% · EM ±9.3%Aug 14 — IV 68% · EM ±7.5%Aug 17 — IV 81% · EM ±6.8%Aug 18 — IV 78% · EM ±5.7%Aug 19 — IV 97% · EM ±5.7%Aug 20 — IV 93% · EM ±3.9%Aug 24 — IV 58% · EM ±12.2%Aug 25 — IV 58% · EM ±11.8%Aug 26 — IV 59% · EM ±11.8%Aug 27 — IV 59% · EM ±11.6%Aug 28 — IV 59% · EM ±11.3%Aug 31 — IV 65% · EM ±11.4%Sep 01 — IV 84% · EM ±14.4%Sep 02 — IV 61% · EM ±10.2%Sep 03 — IV 66% · EM ±10.7%Sep 04 — IV 58% · EM ±9.1%Sep 07 — IV 67% · EM ±9.2%Sep 08 — IV 51% · EM ±6.8%Sep 09 — IV 75% · EM ±9.4%Sep 10 — IV 52% · EM ±6.2%Sep 11 — IV 72% · EM ±7.9%Sep 14 — IV 73% · EM ±6.1%Sep 15 — IV 151% · EM ±10.9%Sep 16 — IV 61% · EM ±3.6%Sep 17 — IV 94% · EM ±3.9%Sep 21 — IV 45% · EM ±9.3%Sep 22 — IV 56% · EM ±11.4%Sep 23 — IV 58% · EM ±11.7%Sep 24 — IV 52% · EM ±10.2%Sep 25 — IV 55% · EM ±10.5%Sep 28 — IV 52% · EM ±9.3%Sep 29 — IV 54% · EM ±9.2%Sep 30 — IV 62% · EM ±10.4%Oct 01 — IV 72% · EM ±11.6%Oct 02 — IV 57% · EM ±8.9%Oct 06 — IV 65% · EM ±8.6%Oct 07 — IV 68% · EM ±8.5%Oct 08 — IV 72% · EM ±8.5%

Sector peers

ORIC
Oric Pharmaceuticals, Inc.
$1.3B $13.17-4.9%
TYRA
Tyra Biosciences, Inc.
$1.4B $20.45-0.7%
DMRA
Damora Therapeutics, Inc.
$1.2B $21.09-2.0%
AVBP
ArriVent BioPharma, Inc.
$1.4B $21.00+9.8%
GHRS
GH Research PLC
$1.4B $18.07-4.4%
RARE
Ultragenyx Pharmaceutical Inc.
$1.5B $15.65-1.7%

OMER earnings FAQ

What is OMER's expected move for earnings?

Options currently price a move of about ±8.5%, or $1.41 per share either way from $16.57.

How does OMER stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.5%, up 1 times and down 1 times.

What is OMER's implied volatility?

OMER's at-the-money implied volatility is about 72% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in